NCT04695847 is a Phase I study assessing the safety and preliminary efficacy of M1231, a bispecific antibody-drug conjugate (ADC) targeting MUC1 and EGFR, in patients with metastatic solid tumors, including NSCLC. This evidence concerns the gene MUC1 and non-small cell lung carcinoma.